Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that its management will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 12:30 p.m. E.T. A live webcast and an archived recording will be available on Avadel’s Investor Relations website for 90 days post-conference.

The company focuses on transforming medicines, with its lead drug candidate, LUMRYZ™, a sodium oxybate formulation designed for narcolepsy treatment.

News Market Reaction – AVDL

-1.96%

-1.96% Session move

In the trading session that priced this news, AVDL declined 1.96%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29 at 12:30 p.m. E.T.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688

FAQ

When is Avadel Pharmaceuticals' fireside chat at the Ladenburg Thalmann Healthcare Conference?

Avadel Pharmaceuticals' fireside chat is scheduled for September 29, 2022, at 12:30 p.m. E.T.

How can I listen to Avadel Pharmaceuticals' fireside chat?

You can listen to Avadel Pharmaceuticals' fireside chat via a live webcast on their Investor Relations website, with an archived recording available for 90 days afterward.

What is Avadel Pharmaceuticals' lead drug candidate?

Avadel Pharmaceuticals' lead drug candidate is LUMRYZ™, an investigational formulation of sodium oxybate for treating narcolepsy.